• Influenza A• Influenza A H1• Influenza A H3• Influenza B• Respiratory Syncytial Virus A

(RSV A)• Respiratory Syncytial Virus B

(RSV B)• Parainfluenza 1• Parainfluenza 2• Parainfluenza 3

• Parainfluenza 4• Human Bocavirus• Human Metapneumovirus

(hMPV)• Rhinovirus/Enterovirus• Adenovirus• Coronavirus HKU1• Coronavirus NL63• Coronavirus OC43• Coronavirus 229E

Bacterial Targets

• Bordetella Pertussis• Bordetella Parapertussis• Chlamydophila Pneumonae• Mycoplasma Pneumoniae

Viral Targets

For more information, visit www.CoreBioLabs.com

3 FDA Cleared Testing3 Rapid Turnaround Time - 24 Hours After Receipt at lab3 Remarkable Detection Capabilities3 Comprehensive Panel of 22 Targets3 Closed-Tube System Minimizes Contamination Risks3 Minimal Hands-On Time3 Customizable, Scalable Throughput

Respiratory Pathogen Panel (RPP)Available today through CoreBioLabsAccurate, Reliable Data in a Fraction of the TimeCoreBioLabs uses the most advanced pathogen panel utilizing the latest FDA cleared platforms. It is a comprehensive, robust assay that detects multiple respiratory pathogens simultaneously in an easy-to-use system.

Flu seasons are unpredictable and vary in severity – statistics underscore the seriousness of the disease. It has been estimated that each year in the United States flu results in:1,2

Disease SummaryRespiratory Burden in the U.S.

• 31.4 million outpatient visits• About 200,000 hospitalizations

• More than $87 billion in total economicburden

Viruses Cases / Year Rate of Hospitalization Death Rate

Seasonal Flu25 – 50 million (U.S.)

600 million (world)

150,000 – 200,000 (U.S.)

3/1,000 (6 – 23 months)

9/1,000 (< 6 months)

36,000 (U.S)

250,000 – 500,000 (world)

RSV125,000 (U.S.)

64 million (world)

15 – 40% RTI (developing world)

70,000 – 126,000 (U.S. infants)

14,000 – 60,000 (U.S. elderly)

160,000 (world)

Para 118% URI

22% LRI

64% croup (U.S. children)

5,800 – 29,000 (U.S.) NA

Para 2 1,800 – 15,600 (U.S.) NA

Para 3 8,700 – 52,000 (U.S) NA

Bacterias 24.1 million NA 160,700 (world)

1. Molinari N-AM, et al. The annual impact of seasonal influenza in the USL Measureing disease burden and costs. Vaccine 2007;25:5086-50962. Morbidity and Mortality Weekly Report (MMWR): Estimates of Deaths Associated with seasonal Influeza - United States, 1976-2007. CDC (Internet) Cited October 2016.

August 27, 2010 / 59/(33);1057-10623. Acute Respiratory Infections. Who (Internet). Cited October 2016. Available from: http://www.who.int/vaccine_research/diseases/ari/en/index.html. 4. Olszewska and Openshaw Expert. Opin Emerg Drugs. 2009;14(2):207-217.5. National Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases (2017) Available from: https://www.cdc.gov/pertussis/fast-facts.html.

Reasons to be tested:• Deaths associated with respiratory

infections were 48,614 in 2003-04

• Respiratory symptoms can includecoughing, nasal discharge, congestion,fever, wheezing, headache, and myalgia

• Due to the similarity of diseases caused bymany viruses and bacteria, diagnosis basedon clinical symptoms alone is difficult

• In children, dual viral infections are common,with 1/3 of children having simultaneous viraland bacterial infections

• Pertussis can cause serious illness in people ofall ages and can even be life-threatening,especially in babies.5